NASDAQ:CRIS - Curis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.42 +0.01 (+0.71 %) (As of 02/21/2020 04:00 PM ET) Add Compare Today's Range$1.36Now: $1.42▼$1.4250-Day Range$1.37MA: $1.60▼$1.8152-Week Range$1.02Now: $1.42▼$2.90Volume36,800 shsAverage Volume117,634 shsMarket Capitalization$47.15 millionP/E RatioN/ADividend YieldN/ABeta2.58 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CRIS Previous Symbol CUSIP23126910 CIK1108205 Webhttp://www.curis.com/ Phone617-503-6500Debt Debt-to-Equity RatioN/A Current Ratio6.93 Quick Ratio6.93Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.43 million Price / Sales4.52 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-10.14Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-32,580,000.00 Net Margins-299.47% Return on EquityN/A Return on Assets-56.69%Miscellaneous Employees55 Outstanding Shares33,203,000Market Cap$47.15 million Next Earnings Date3/24/2020 (Estimated) OptionableOptionable Receive CRIS News and Ratings via Email Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CRIS Rates by TradingView Curis (NASDAQ:CRIS) Frequently Asked Questions What is Curis' stock symbol? Curis trades on the NASDAQ under the ticker symbol "CRIS." When did Curis' stock split? How did Curis' stock split work? Curis's stock reverse split on the morning of Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) announced its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.41) by $0.15. The biotechnology company had revenue of $2.36 million for the quarter, compared to analysts' expectations of $2.41 million. View Curis' Earnings History. When is Curis' next earnings date? Curis is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Curis. Has Curis been receiving favorable news coverage? News coverage about CRIS stock has been trending somewhat negative on Friday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Curis earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Curis. Are investors shorting Curis? Curis saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 258,800 shares, a decrease of 14.9% from the January 15th total of 304,000 shares. Based on an average daily volume of 264,100 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.9% of the company's stock are sold short. View Curis' Current Options Chain. Who are some of Curis' key competitors? Some companies that are related to Curis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Novavax (NVAX), Celldex Therapeutics (CLDX), Micron Technology (MU), Agenus (AGEN), CTI BioPharma (CTIC), Geron (GERN), Inovio Pharmaceuticals (INO), Zynga (ZNGA) and Catalyst Pharmaceuticals (CPRX). Who are Curis' key executives? Curis' management team includes the folowing people: Mr. James E. Dentzer, Pres, CEO & Director (Age 52)Dr. Robert E. Martell, Head of R&D (Age 56)Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 60)Mr. Bill Steinkrauss, Corp. Controller & Sr. Director of Fin.Mr. Daniel R. Passeri M.Sc., MSc., J.D., Consultant (Age 58) Who are Curis' major shareholders? Curis' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.63%), Focused Wealth Management Inc (0.18%), Virtu Financial LLC (0.09%) and CAPROCK Group Inc. (0.06%). Company insiders that own Curis stock include James E Dentzer, Kenneth I Kaitin and Robert Martell. View Institutional Ownership Trends for Curis. Which institutional investors are buying Curis stock? CRIS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC, Focused Wealth Management Inc and CAPROCK Group Inc.. View Insider Buying and Selling for Curis. How do I buy shares of Curis? Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Curis' stock price today? One share of CRIS stock can currently be purchased for approximately $1.42. How big of a company is Curis? Curis has a market capitalization of $47.15 million and generates $10.43 million in revenue each year. Curis employs 55 workers across the globe.View Additional Information About Curis. What is Curis' official website? The official website for Curis is http://www.curis.com/. How can I contact Curis? Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected] MarketBeat Community Rating for Curis (NASDAQ CRIS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 623 (Vote Outperform)Underperform Votes: 559 (Vote Underperform)Total Votes: 1,182MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: What is a resistance level?
